The physicians at the Cornea Center at Northeast Ohio Eye Surgeons offer the most technologically and surgically advanced care, delivered with kindness and compassion. Doctors Marc Jones, M.D. and Larry Lohman, M.D. are fellowship-trained in cornea care and surgery. They are nationally recognized as leaders in corneal treatments and innovation. Northeast Ohio Eye Surgeons has been selected by the National Institute of Health and other organizations to participate in studies to advance and improve corneal treatments and surgeries. Our cornea specialists are delighted to share their expertise with you.
What Is the Cornea?
The cornea is the clear, dome-shaped window that covers the front of the eye. It is similar to the glass face of a watch or the outermost glass lens in a camera. Its purpose is to focus light entering the eye and protect the eye from the environment. Healthy corneas are transparent so they can transmit and bend light rays onto the retina, in the back of the eye. However, if the cornea becomes scarred or distorted due to injury or disease, the light rays entering the eye will be distorted as well, leading to significantly impaired vision. Conditions such as keratoconus and Fuchs’ dystrophy are leading causes of corneal damage.
Keratoconus, often referred to as “KC,” is an eye condition in which the cornea weakens and thins over time, causing the development of a cone-like bulge and optical irregularity of the cornea. This rare condition typically first appears in individuals in their teens or early 20s.
Using Photrexa® Viscous (riboflavin 5’-phosphate in 20% dextran ophthalmic solution), Photrexa® (riboflavin 5’-phosphate ophthalmic solution) and the KXL® system, the iLink corneal cross-linking procedure from Glaukos is the only FDA-approved therapeutic treatment for patients with progressive keratoconus and corneal ectasia following refractive surgery.
iLink: the ONLY Cross-Linking Procedure Approved by the FDA
iLink is the only FDA-approved cross-linking procedure that slows or halts progressive keratoconus to help you preserve vision & is covered by insurance. Clinical trials demonstrated that the iLink cross-linking procedure is effective in slowing or halting the progression of keratoconus. While manufacturers of FDA-approved drugs and devices are required to report adverse experiences to the FDA, there is no equivalent reporting required for unapproved products, which may present a risk to public safety. In the study that led to the FDA-approval of iLink, patients who did not undergo cross-linking continued to progress, while patients who underwent iLink cross-linking did not progress.